The above results indicate that knockdown of BMAL1 can render AML cells more sensitive to anticancer drugs, including venetoclax, dasatinib, and sorafenib, suggesting its potential as a novel therapeutic target for AML. This evidence concerns the gene BMAL1 and acute myeloid leukemia.